A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of 40 mg a day of istradefylline
(KW-6002) for reducing the percentage of awake time spent in the OFF state in patients with
advanced Parkinson's disease treated with levodopa.